Sensei

Sensei Biotherapeutics is a clinical-stage biotechnology company focused on discovering and developing next-generation immunotherapies for cancer. The company leverages its proprietary TMAb (Tumor Microenvironment Activated biologics) platform to engineer conditionally active antibodies that target immune checkpoints specifically within the acidic environment of tumors. Its lead program, SNS-101, is a monoclonal antibody targeting VISTA, designed to overcome immune suppression in solid tumors. Sensei's pipeline also includes bispecific antibodies and programs targeting other myeloid checkpoints like VSIG4 and CD39. By focusing on the tumor microenvironment, the company aims to improve the efficacy and safety of immunotherapy for patients with difficult-to-treat cancers.